Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gritstone Oncology Inc (GRTS)
NASDAQ:GRTS
Gritstone Oncology (GRTS) Stock Price & Analysis
743 Followers
GRTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.67 - $3.33
Previous Close$0.96
Volume4.20M
Average Volume (3M)2.79M
Market Cap
$103.13M
Enterprise Value$128.62M
Total Cash (Recent Filing)$79.29M
Total Debt (Recent Filing)$104.78M
Price to Earnings (P/E)-0.8
Beta1.72
Next Earnings
May 09, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding98,065,594
10 Day Avg. Volume2,097,126
30 Day Avg. Volume2,789,133
Standard Deviation0.52
R-Squared0.00441
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.65
Price to Sales (P/S)5.78
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.87
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-1.00
Forecast
1Y Price Target
$5.60Price Target Upside481.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Gritstone Oncology News
Bulls Say, Bears Say
Bulls Say
Government SupportThe $430M grant from BARDA to Gritstone bio highlights the government's support for vaccines with greater immunogenicity and durability.
Product DevelopmentGMP-grade materials being used in the trial suggest a commercially-ready product, potentially shortening the timeline to a BLA submission.
Technology AdvancementGRTS's technology, which includes a self-replicating component, drives approximately 10 times higher immunogenicity compared to MRNA’s first-generation mRNA technology.
Bears Say
Clinical Trial SetbacksInterim results do little to de-risk the Granite program.
Financial StrainShares were trading down as much as 40% as a result of the proposed financing after the data release.
Operational ChallengesGritstone bio announced a 40% workforce reduction following a delay in a significant trial, indicating a restructuring phase within the company.
---
Ownership Overview
21.66% Insiders
7.90% Mutual Funds
11.15% Other Institutional Investors
59.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GRTS FAQ
What was Gritstone Oncology Inc’s price range in the past 12 months?
Gritstone Oncology Inc lowest stock price was $0.67 and its highest was $3.33 in the past 12 months.
What is Gritstone Oncology Inc’s market cap?
Currently, no data Available
When is Gritstone Oncology Inc’s upcoming earnings report date?
Gritstone Oncology Inc’s upcoming earnings report date is May 09, 2024 which is in 2 days.
How were Gritstone Oncology Inc’s earnings last quarter?
Gritstone Oncology Inc released its earnings results on Mar 05, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.327 by $0.067.
Is Gritstone Oncology Inc overvalued?
According to Wall Street analysts Gritstone Oncology Inc’s price is currently Undervalued.
Does Gritstone Oncology Inc pay dividends?
Gritstone Oncology Inc does not currently pay dividends.
What is Gritstone Oncology Inc’s EPS estimate?
Gritstone Oncology Inc’s EPS estimate is -$0.32.
How many shares outstanding does Gritstone Oncology Inc have?
Gritstone Oncology Inc has 107,130,800 shares outstanding.
What happened to Gritstone Oncology Inc’s price movement after its last earnings report?
Gritstone Oncology Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.327. Following the earnings report the stock price went up 6.863%.
Which hedge fund is a major shareholder of Gritstone Oncology Inc?
Among the largest hedge funds holding Gritstone Oncology Inc’s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc’s shares valued at 7M.
---
Gritstone Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.60 (481.70% Upside)
$5.60 (481.70% Upside)
Blogger Sentiment
Bullish
GRTS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 87.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.20%
12-Months-Change
Fundamentals
Return on Equity
-124.41%
Trailing 12-Months
Asset Growth
-26.16%
Trailing 12-Months
Company Description
Gritstone Oncology Inc
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
---
GRTS Company Deck
---
GRTS Earnings Call
Q1 2023
0:00 / 0:00
---
GRTS Stock 12 Months Forecast
Average Price Target
$5.60
▲(481.70% Upside)
Technical Analysis
Corvus Pharmaceuticals
―
Voyager Therapeutics
―
Rocket Pharmaceuticals
―
Adaptimmune Therapeutics
―
Best Analysts Covering GRTS
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-12.94%
reiterated a buy rating 2 months ago
Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -12.94% per trade.
---